Monoclonal Antibodies Market

Monoclonal Antibodies Market Size (2022 to 2027)

As per our report, the size of the global monoclonal antibodies market was worth USD 39.10 Billion in 2022. This figure is estimated to be growing at a CAGR of 5.30% and will reach USD 50.62 Billion by 2027.

Monoclonal Antibodies Market Share insights: 

• Based on Source, the murine segment is projected to have the fastest CAGR during the forecast period.
• Based on End-user, the hospital segment registered the largest market share of  41.24% in 2021.
• North American Monoclonal antibodies market captured a significant share of the global market and is expected to reach USD 16.76 Billion by 2027.
• Aisa Pacific monoclonal antibodies market showcases the fastest CAGR of 7.21% during the forecast period.  

In biochemistry and molecular biology, monoclonal antibodies play an important role in detecting or purifying substances. These are derived from identical immune cells and can easily bind to a particular antigen. Hybridoma technology is designing monoclonal antibodies that will enhance the immunity system naturally. It is approved by the U.S Food and Drug Administration (FDA) as it is an innovative product in molecular biology for disease treatment. Many global companies are focusing on developing molecular agents to treat various diseases like Cancer.

Impact of COVID-19 on the global monoclonal antibodies market:

The outburst of COVID-19 has brought the world to a standstill. This health crisis has brought an unprecedented impact on businesses in every sector, including the healthcare sector. The COVID-19 impact has positively influenced the monoclonal antibodies market as these antibodies prevent and treat early infections of COVID-19. Many companies are in a race to find an efficient vaccine to treat novel coronavirus disease with the help of monoclonal antibodies. Government organizations support the researchers by approving emergency

MARKET DRIVERS:

Increasing incidences of chronic diseases such as Cancer, diabetes, and others worldwide are undoubtedly vital factors for the worldwide monoclonal antibodies market to grow.

The demand to ensure quality healthcare services is accelerating the market's growth.

Also, the invention of new monoclonal antibody applications significantly influences this market's growth rate. Furthermore, the rise in healthcare infrastructure investment will likely boost the global mABs market demand. The development of new molecules is expected to play a prominent role in the market's future due to this technology's cost-effectiveness.

The advancement of genomics research and development activities and the emergence of technologically advanced genetic platforms, such as next-generation sequencing, have contributed significantly to the market and helped the existing companies in the global mABs market grow further.

The emergence of advanced technology, the launch of innovative products in the biotechnology field, and growth in the economy in developed and developing countries are surging the demand for the monoclonal antibodies market. Growing knowledge of genomics, the trend toward next-generation sequencing, and ease in the availability of various resources used in the research centers fuel the market's demand. The rise in awareness of therapies and other biological parameters impacts the market's growth.

MARKET RESTRAINTS:

Less available raw materials used to manufacture drugs restrain the market's demand.

REPORT COVERAGE:

This research report on Global Monoclonal Antibodies Market has been segmented and sub-segmented based on the Source, indication, end-user, application, and Region.

Monoclonal Antibodies Market - By Source:

• Murine
• Chimeric
• Humanized
• Human

Based on the Source, the murine segment held the largest share of the global monoclonal antibodies market in 2021 due to the development of modern antibody production techniques and immunoglobulins for therapeutic and analytical applications. On the other hand, the chimeric segment is expected to have the highest growth rate in the coming years. An increasing number of people suffering from various health disorders is a specific factor for this segment to grow.

On the other hand, the humanized monoclonal segment is one of the most lucrative segments and is expected to grow at a healthy rate during the forecast period. The extensive adoption of innovative techniques for treating various diseases, such as Cancer and inflammatory disorders, propels this segment's demand. In addition, progressive genetic engineering technology engaged in its production is one of the significant factors driving the segment demand.

Monoclonal Antibodies Market - By Indication:

• Cancer
  • Blood cancer
  • Breast cancer
  • Colorectal cancer
  • Lung cancer
  • Pancreatic Cancer
  • Others
• Autoimmune Diseases
• Infectious Diseases
• Cardiovascular Diseases
• CNS Disorders
• Others (Inflammatory, Microbial Diseases, & Others)

Based on the indication, the cancer disease segment is ruling the market currently andwill accountd for a dominating share of the mABs market in 2021. Adopting sedentary lifestyles and changing food habits are some attributes for the cancer segment to grow. Therefore, this segment is expected to continue its dominance throughout the forecast period. The segment growth is further majorly driven by the high increase in the incidence of cancer and healthcare reimbursement policies. In addition, intensifying the drug pipeline integrated with treatment approvals and clinical trials is projected to generate profitable growth opportunities in the monoclonal antibodies market.

Monoclonal Antibodies Market By End-User:

• Hospitals /Clinics
• Research Institute
• Diagnostic Laboratories

Based on end-user, the hospitals /clinics are forecasted to register the most significant share of the monoclonal antibodies market and are central to the increasing healthcare centers and clinics' scale. Besides, the growing geriatric population is enhancing the market's growth rate. In addition, the rising patient population and a growing number of chronic disease patients are increasing the demand for this segment. Furthermore, this segment is also expected to be favored by increasing chronic ailments, growing healthcare expenses, and raising awareness among the patient population about alternative treatments.

Monoclonal Antibodies Market - By Application:

• Medical
• Experimental
• Western Blot
• ELISA
• Radioimmune Assays
• Immunofluorescence
• Others

Based on the application, the medical segment led the monoclonal antibodies market worldwide in 2021, owing to a rise in research and development activities. Monoclonal antibodies are replicas of the human body's antibodies made in a laboratory and used to boost the immune system. These are used in medicals in such a way that monoclonal antibodies as therapies and for other treatments of cancers. These are used as immunotherapy because these immune system fight against Cancer. In addition, different types of vaccines are available based on monoclonal antibodies.

The ELISA segment fosters the monoclonal antibody market during the forecast period. ELISA methods are used on monoclonal antibodies, which drives the segment growth forward. This method detects and quantifies a specific protein in a complex mixture.

Monoclonal Antibodies Market by Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East Africa

Geographically, North America Monoclonal Antibodies Market dominates the global market due to the well-established healthcare infrastructure in this Region, the increased importance given to state infection control and management, and the growing prevalence of lifestyle-related health issues. Furthermore, the market will continue to grow during the forecast period, owing to amplified public investments in cancer research and technological development. Therapeutic monoclonal antibodies have been increasing yearly, and it is estimated that 106 monoclonal antibodies have been approved in the United States. In Canada, monoclonal antibodies are used more widely due to the increase in cases of Covid-19 infection. Researchers in Canada have manufactured different monoclonal antibodies to treat many diseases, such as severe asthma, rheumatoid arthritis, multiple sclerosis, infectious diseases, and Cancer.

The Europe Monoclonal Antibodies Market is predicted to grow at a compound annual growth rate (CAGR %) from 2022 to 2027. The European Commission has advised the European Medicines Agency (EMA) to follow the guidelines that medicine should contain monoclonal antibodies against the spike protein of the SARS-CoV-2 virus. Europe has been in an advanced state to approve different types of monoclonal antibodies for different diseases. In Germany, Sotrovimab is another COVID-19 treatment option available in this Region to reduce infection rates. The European Commission also approved Xevudy in 2021 to treat COVID-19 in adults over 12 years.

The Asia-Pacific Monoclonal Antibodies Market is also anticipated to increase significantly due to improved lifestyles and increasing awareness about mAbs among patients, advanced research, and development costs. However, due to the lack of penetration, the Asia Pacific market has a high potential to grow during the forecast period. 

 'The MEA Monoclonal Antibodies Market is witnessed to reach a CAGR of 12.95% during the forecast period. In Middle East Africa, coronavirus has infected many people with high mortality. Therefore, this Region provides highly effective therapeutics and vaccines against the coronavirus to save human lives.

KEY MARKET PARTICIPANTS & SHARE INSIGHTS:

Companies leading the global monoclonal antibodies market profiled in the report are GlaxoSmithKline PLC, Novartis AG, Pfizer Inc., Thermo Fisher Scientific inc., Eli Lilly, And Shanghai Junshi Bioscience Co., Ltd.Company, Seattle Genetics, Bristol-Myers Squibb, F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Lt.

RECENT DEVELOPMENTS:

• In January 2020, Pfizer announced to launch Bavencio (avelumab) vaccine, which is used to treat cancer patients.
• In February 2020, GlaxoSmithKline ple registered to introduce belantamab mafodotin, which will act upon the B-cell maturation antigen.
• In 2022, Sanofi and Blackstone signed an agreement to develop and deliver the anti-CD38 antibody, Sarclisa, to treat patients with multiple myeloma.
• In 2021, Atlas Antibodies signed an agreement with T-Cure Bioscience, a company focused on developing autologous T Cell Receptor Therapy (TCR-T) products to treat solid tumors, and also had an agreement for the development, manufacture, and supply of CT83 (KK-LC-1) monoclonal antibodies.
• In 2021, Kyowa Kirin Co., Ltd. partnered with Amgen to study KHK4083/AMG 451 at the European Academy of Dermatology. It is the anti-OX40 fully human monoclonal antibody used for the development of the treatment of moderate-to-severe atopic dermatitis.
• Roche's antibody cocktail was granted by the Central Drugs Standards Control Organization in India in 2021.
• In April 2021, BLA (Biological License Application), an American regulatory agency, merged to manufacture balstilimab as monotherapy to indicate Cervical Cancer.